Home › Trial NCT03030131
Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer
- Trial IDNCT03030131
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorIntergroupe Francophone de Cancerologie Thoracique
- Enrollment50
- Start date2017-01-12
- ConditionsCarcinoma, Non-Small-Cell Lung
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.